The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Managed Access program to launch for belinostat for patients with Peripheral T-Cell Lymphoma (PTCL) in Europe
On 24th April 2017, it was announced that the Idis Managed Access division of Clinigen Group and Onxeo have agreed to launch a Managed Access program for belinostat (marketed as BELEODAQ® in the U.S.) in Europe.
The program will allow physicians to request belinostat for specific patients for whom alternative treatment options are not currently available. On a named patient basis, this will allow access to belinostat ahead of a potential EU approval. The program will be available in 13 European countries: France, Spain, Germany, Belgium, Italy, The United Kingdom, Luxembourg, Austria, Denmark, Sweden, Norway, Finland, and The Netherlands.
Belinostat is a HDAC inhibitor used to treat R/R PTCL and in July 2014 received accelerated approval by the U.S. Food and Drug Administration (FDA) in this indication, primarily due to the large unmet need in this group of patients. Currently, belinostat does not hold any approvals in Europe.
References